Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

"These data confirm Zepbound as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan," said Leonard Glass ...

Zepbound is also prescribed to treat moderate to severe obstructive sleep apnea in adults with obesity ... such as your treatment plan and the pharmacy you use. Here are a few things to consider ...

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna (NASDAQ: SEPN) to co-develop oral small molecule therapies targeting obesity, type 2 diabetes,